Supplementation of Alpha-linolenic Acid (ALA)-Rich Oil in Humans

NCT ID: NCT01317290

Last Updated: 2013-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to investigate the accumulation of n-3 LC-PUFA (EPA, DPA and DHA) in human lipids by oral supplementation of ALA-rich linseed oil. In addition, the accumulation of n-3 LC-PUFA is compared between subpopulations of different age, gender and physiological conditions (overweight, increased serum total cholesterol).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

N-3 PUFA are important for human health and nutrition. Unfortunately, the land-based n-3 ALA is a limited precursor for the formation of n-3 LC-PUFA. The conversion of ALA depends on the rate-limiting ∆6-desaturation.

The first objective of this study is to investigate differences of the accumulation of n-3 LC-PUFA (EPA, DPA and DHA) in human lipids during supplementation of ALA-rich linseed oil dependent on age, gender and physiological conditions (overweight, increased serum total cholesterol). One study group will receive fish oil with mainly EPA as positive control.

The second objective is to compare the n-3 LC-PUFA enrichment during the linseed oil supplementation (study LSEP H50-KK) with the n-3 LC-PUFA enrichment during the further Echium oil supplementation (study LSEP H42-KK). The second study will be the control for the first study.

Therefore, it is planned to recruit the same subjects for the linseed oil supplementation.

Eighty volunteers will be recruited and allocated into four study groups depending on age and BMI. Three groups (each n=20) will receive daily ca. 15 g linseed oil (mean age: 25 and 55 years; mean BMI \< 25; and mean age 55 and BMI \> 25). One group (n=20) will receive n-3PUFA free olive oil (mean age 25 and 55, BMI \< 25). The double-blind, randomized, parallel-designed study will start with a two-weeks run-in period, followed by an eight-weeks supplementation period. After the run-in period, one week and eight weeks of oil supplementation blood will be drawn and 24-h urine will be sampled.

Altogether, the fatty acid distribution after Echium oil and linseed oil supplementation from similar subjects can be statistically analysed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight Hypercholesterolemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Conversion of ALA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

linseed oil; young

ALA rich linseed oil to younger subjects (18-35 years)

Group Type EXPERIMENTAL

linseed oil

Intervention Type DIETARY_SUPPLEMENT

linseed oil; older

ALA rich linseed oil to older, normalweight subjects (BMI \<25, age 49-69 years)

Group Type EXPERIMENTAL

linseed oil

Intervention Type DIETARY_SUPPLEMENT

linseed oil older, overweight

ALA-rich linseed oil to older, normalweight subjects (BMI \>25, age 49-69 years)

Group Type EXPERIMENTAL

linseed oil

Intervention Type DIETARY_SUPPLEMENT

olive oil

n3-PUFA free control oil to normalweight subjects (BMI \<25)

Group Type EXPERIMENTAL

n-3 PUFA free olive oil

Intervention Type DIETARY_SUPPLEMENT

negative control

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

n-3 PUFA free olive oil

negative control

Intervention Type DIETARY_SUPPLEMENT

linseed oil

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy subjects

Exclusion Criteria

* cholesterol lowering drugs
* chronic diseases
* pregnancy, lactation
* intake of nutritional supplements
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

German Research Foundation

OTHER

Sponsor Role collaborator

University of Jena

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gerhard Jahreis

Prof. Dr. habil.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Katrin Kuhnt, Dr. rer. nat

Role: PRINCIPAL_INVESTIGATOR

University of Jena, Insitute of Nutrition

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Friedrich Schiller University of Jena

Jena, Thuringia, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Kuhnt K, Weiss S, Kiehntopf M, Jahreis G. Consumption of echium oil increases EPA and DPA in blood fractions more efficiently compared to linseed oil in humans. Lipids Health Dis. 2016 Feb 18;15:32. doi: 10.1186/s12944-016-0199-2.

Reference Type DERIVED
PMID: 26892399 (View on PubMed)

Grindel A, Staps F, Kuhnt K. Cheek cell fatty acids reflect n-3 PUFA in blood fractions during linseed oil supplementation: a controlled human intervention study. Lipids Health Dis. 2013 Nov 14;12:173. doi: 10.1186/1476-511X-12-173.

Reference Type DERIVED
PMID: 24229084 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H50-11-KK

Identifier Type: -

Identifier Source: org_study_id